International Clinical Trial: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444489) titled 'A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Biogen

Condition: Antibody-mediated Rejection

Intervention: Drug: Felzartamab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: March 10, 2026

Target Sample Size: 120

To know more, visit https://clinicaltrials.gov/study/NCT0744448...